The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The antibacterial effect of fatty acids on Helicobacter pylori infection

  • Jung, Sung Woo (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Lee, Sang Woo (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine)
  • Received : 2015.10.05
  • Accepted : 2015.12.09
  • Published : 2016.01.01
⟨ Previous Next ⟩

Abstract

Eradication of Helicobacter pylori is recommended for the management of various gastric diseases, including peptic ulcers and mucosa-associated lymphoid tissue lymphoma. Because of the increasing prevalence of antibiotic resistance, the eradication rates of antibiotic-based therapies have decreased. Therefore, alternative treatments should be considered. The antibacterial properties of fatty acids (FAs) have been investigated in various organisms, including H. pylori. Some FAs, particularly polyunsaturated FAs, have been shown to have bactericidal activity against H. pylori in vitro; however, their antibacterial effects in vivo remain controversial. Poor solubility and delivery of FAs may be important reasons for this discrepancy. Recently, a series of studies demonstrated the antibacterial effects of a liposomal formulation of linolenic acid against H. pylori, both in vitro and in vivo. Further research is needed to improve the bioavailability of FAs and apply them in clinical use.

Keywords

References

  1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186. https://doi.org/10.1056/NEJMra020542
  2. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664. https://doi.org/10.1136/gutjnl-2012-302084
  3. Graham DY. Roadmap for elimination of gastric cancer in Korea. Korean J Intern Med 2015;30:133-139. https://doi.org/10.3904/kjim.2015.30.2.133
  4. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001. https://doi.org/10.1053/j.gastro.2007.07.008
  5. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-414.
  6. Bang CS, Baik GH. Time to learn from the past and prepare for the future in Helicobacter pylori eradication. Korean J Intern Med 2015;30:789-791. https://doi.org/10.3904/kjim.2015.30.6.789
  7. Gisbert JP. Rescue therapy for Helicobacter pylori infection 2012. Gastroenterol Res Pract 2012;2012:974594.
  8. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011;17:3971-3975. https://doi.org/10.3748/wjg.v17.i35.3971
  9. Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP. Fatty acids and derivatives as antimicrobial agents. Antimicrob Agents Chemother 1972;2:23-28. https://doi.org/10.1128/AAC.2.1.23
  10. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microbiol Biotechnol 2010;85:1629-1642. https://doi.org/10.1007/s00253-009-2355-3
  11. Hazell SL, Markesich DC, Evans DJ, Evans DG, Graham DY. Influence of media supplements on growth and survival of Campylobacter pylori. Eur J Clin Microbiol Infect Dis 1989;8:597-602. https://doi.org/10.1007/BF01968136
  12. Hazell SL, Graham DY. Unsaturated fatty acids and viability of Helicobacter (Campylobacter) pylori. J Clin Microbiol 1990;28:1060-1061.
  13. Thompson L, Cockayne A, Spiller RC. Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration. Gut 1994;35:1557-1561. https://doi.org/10.1136/gut.35.11.1557
  14. Khulusi S, Ahmed HA, Patel P, Mendall MA, Northfield TC. The effects of unsaturated fatty acids on Helicobacter pylori in vitro. J Med Microbiol 1995;42:276-282. https://doi.org/10.1099/00222615-42-4-276
  15. Petschow BW, Batema RP, Ford LL. Susceptibility of Helicobacter pylori to bactericidal properties of medium-chain monoglycerides and free fatty acids. Antimicrob Agents Chemother 1996;40:302-306.
  16. Bergsson G, Steingrimsson O, Thormar H. Bactericidal effects of fatty acids and monoglycerides on Helicobacter pylori. Int J Antimicrob Agents 2002;20:258-262. https://doi.org/10.1016/S0924-8579(02)00205-4
  17. Sun CQ, O'Connor CJ, Roberton AM. Antibacterial actions of fatty acids and monoglycerides against Helicobacter pylori. FEMS Immunol Med Microbiol 2003;36:9-17. https://doi.org/10.1016/S0928-8244(03)00008-7
  18. Correia M, Michel V, Matos AA, et al. Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization. PLoS One 2012;7:e35072. https://doi.org/10.1371/journal.pone.0035072
  19. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495-505. https://doi.org/10.1080/07315724.2002.10719248
  20. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83(6 Suppl):1505S-1519S. https://doi.org/10.1093/ajcn/83.6.1505S
  21. Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol 2009;158:960-971. https://doi.org/10.1111/j.1476-5381.2009.00290.x
  22. Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 2012;32:203-227. https://doi.org/10.1146/annurev-nutr-071811-150726
  23. Correia M, Michel V, Osorio H, et al. Crosstalk between Helicobacter pylori and gastric epithelial cells is impaired by docosahexaenoic acid. PLoS One 2013;8:e60657. https://doi.org/10.1371/journal.pone.0060657
  24. Lee SE, Lim JW, Kim JM, Kim H. Anti-inflammatory mechanism of polyunsaturated fatty acids in Helicobacter pylori-infected gastric epithelial cells. Mediators Inflamm 2014;2014:128919.
  25. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983;245(5 Pt 1):G601-G623.
  26. Duggan AE, Atherton JC, Cockayne A, et al. Clarification of the link between polyunsaturated fatty acids and Helicobacter pylori-associated duodenal ulcer disease: a dietary intervention study. Br J Nutr 1997;78:515-522. https://doi.org/10.1079/BJN19970171
  27. Frieri G, Pimpo MT, Palombieri A, et al. Polyunsaturated fatty acid dietary supplementation: an adjuvant approach to treatment of Helicobacter pylori infection. Nutr Res 2000;20:907-916. https://doi.org/10.1016/S0271-5317(00)00182-2
  28. Yu HN, Zhu J, Pan WS, Shen SR, Shan WG, Das UN. Effects of fish oil with a high content of n-3 polyunsaturated fatty acids on mouse gut microbiota. Arch Med Res 2014;45:195-202. https://doi.org/10.1016/j.arcmed.2014.03.008
  29. Pagkalos VA, Moschandreas J, Kiriakakis M, Roussomoustakaki M, Kafatos A, Kouroumalis E. Fatty acid composition of subcutaneous adipose tissue and gastric mucosa: is there a relation with gastric ulceration? BMC Gastroenterol 2009;9:9. https://doi.org/10.1186/1471-230X-9-9
  30. Meier R, Wettstein A, Drewe J, Geiser HR; Swiss Helicobacter-Study Group. Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001;15:851-855. https://doi.org/10.1046/j.1365-2036.2001.00989.x
  31. Khandouzi N, Shidfar F, Agah S, Hosseini AF, Dehnad A. Comparison of the effects of eicosapentaenoic acid and docosahexaenoic acid on the eradication of Helicobacter pylori infection, serum inflammatory factors and total antioxidant capacity. Iran J Pharm Res 2015;14:149-157.
  32. Lacey RW, Lord VL. Sensitivity of staphylococci to fatty acids: novel inactivation of linolenic acid by serum. J Med Microbiol 1981;14:41-49. https://doi.org/10.1099/00222615-14-1-41
  33. Dyall SC. Methodological issues and inconsistencies in the field of omega-3 fatty acids research. Prostaglandins Leukot Essent Fatty Acids 2011;85:281-285. https://doi.org/10.1016/j.plefa.2011.04.009
  34. Glassman HN. Surface active agents and their application in bacteriology. Bacteriol Rev 1948;12:105-148.
  35. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-160. https://doi.org/10.1038/nrd1632
  36. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36-48. https://doi.org/10.1016/j.addr.2012.09.037
  37. Thamphiwatana S, Gao W, Pornpattananangkul D, et al. Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Mater Chem B Mater Biol Med 2014;2:8201-8207. https://doi.org/10.1039/C4TB01110D
  38. Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang L. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm 2012;9:2677-2685. https://doi.org/10.1021/mp300243w
  39. Jung SW, Thamphiwatana S, Zhang L, Obonyo M. Mechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pylori. PLoS One 2015;10:e0116519. https://doi.org/10.1371/journal.pone.0116519
  40. Thamphiwatana S, Gao W, Obonyo M, Zhang L. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proc Natl Acad Sci U S A 2014;111:17600-17605. https://doi.org/10.1073/pnas.1418230111

Cited by

  1. Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease vol.7, pp.None, 2016, https://doi.org/10.3389/fimmu.2016.00290
  2. PREVALENCE OF HELICOBACTER PYLORI TEN YEARS AGO COMPARED TO THE CURRENT PREVALENCE IN PATIENTS UNDERGOING UPPER ENDOSCOPY vol.29, pp.3, 2016, https://doi.org/10.1590/0102-6720201600030006
  3. Cytotoxic and Antimicrobial Activities of Cantharellus cibarius Fr. (Cantarellaceae) vol.20, pp.8, 2017, https://doi.org/10.1089/jmf.2016.0176
  4. Effectiveness of omega-3 polyunsaturated fatty acids against microbial pathogens vol.19, pp.4, 2016, https://doi.org/10.1631/jzus.b1700063
  5. Antibacterial Free Fatty Acids and Monoglycerides: Biological Activities, Experimental Testing, and Therapeutic Applications vol.19, pp.4, 2016, https://doi.org/10.3390/ijms19041114
  6. Eradication of Helicobacter pylori: the power of nanosized formulations vol.15, pp.5, 2016, https://doi.org/10.2217/nnm-2019-0329
  7. Effects of Multi-Strain Probiotics on Immune Responses and Metabolic Balance in Helicobacter pylori -Infected Mice vol.12, pp.8, 2020, https://doi.org/10.3390/nu12082476